CY1113038T1 - Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου - Google Patents
Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινουInfo
- Publication number
- CY1113038T1 CY1113038T1 CY20121100466T CY121100466T CY1113038T1 CY 1113038 T1 CY1113038 T1 CY 1113038T1 CY 20121100466 T CY20121100466 T CY 20121100466T CY 121100466 T CY121100466 T CY 121100466T CY 1113038 T1 CY1113038 T1 CY 1113038T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- methods
- trietercyclic
- units
- cancer treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 4
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000005170 neoplastic cell Anatomy 0.000 abstract 1
- 230000001613 neoplastic effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47474103P | 2003-05-30 | 2003-05-30 | |
| EP04735171A EP1644363B1 (en) | 2003-05-30 | 2004-05-28 | Triheterocyclic compounds, compositions, and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1113038T1 true CY1113038T1 (el) | 2016-04-13 |
Family
ID=33490730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100466T CY1113038T1 (el) | 2003-05-30 | 2012-05-22 | Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US7425553B2 (enExample) |
| EP (1) | EP1644363B1 (enExample) |
| JP (1) | JP4980715B2 (enExample) |
| KR (1) | KR101168441B1 (enExample) |
| CN (1) | CN1832939B (enExample) |
| AT (1) | ATE546456T1 (enExample) |
| AU (1) | AU2004242928B2 (enExample) |
| BR (1) | BRPI0410870A (enExample) |
| CA (1) | CA2527583C (enExample) |
| CY (1) | CY1113038T1 (enExample) |
| DK (1) | DK1644363T3 (enExample) |
| ES (1) | ES2382377T3 (enExample) |
| HR (1) | HRP20120379T1 (enExample) |
| IL (1) | IL172189A (enExample) |
| MX (1) | MXPA05012799A (enExample) |
| NO (1) | NO333006B1 (enExample) |
| NZ (1) | NZ543897A (enExample) |
| PL (1) | PL1644363T3 (enExample) |
| PT (1) | PT1644363E (enExample) |
| RU (1) | RU2360913C2 (enExample) |
| SI (1) | SI1644363T1 (enExample) |
| WO (1) | WO2004106328A1 (enExample) |
| ZA (1) | ZA200509718B (enExample) |
Families Citing this family (156)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060035945A1 (en) * | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| EP1746888A2 (en) * | 2004-05-13 | 2007-01-31 | Viropharma Incorporated | Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| US8420693B2 (en) * | 2004-12-28 | 2013-04-16 | Gemin X Pharmaceuticals Canada Inc. | Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases |
| WO2006089397A1 (en) * | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| US7994360B2 (en) | 2005-05-16 | 2011-08-09 | Xtl Biopharmaceuticals Ltd. | Benzofuran compounds |
| US20080051400A1 (en) * | 2006-07-06 | 2008-02-28 | Gemin X Biotechnologies Inc. | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound |
| JP5055377B2 (ja) | 2006-12-22 | 2012-10-24 | シェーリング コーポレイション | ［５，６−環］環形成インドール誘導体およびその使用方法 |
| JP5079818B2 (ja) * | 2006-12-22 | 2012-11-21 | メルク・シャープ・アンド・ドーム・コーポレーション | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 |
| KR20090106539A (ko) | 2006-12-22 | 2009-10-09 | 쉐링 코포레이션 | Ｈｃｖ 및 관련 바이러스 감염을 치료 또는 예방하기 위한 4,5-환 환상 인돌 유도체 |
| US9649499B2 (en) | 2007-03-28 | 2017-05-16 | Medtronic ATS Medical, Inc. | Method for inhibiting platelet interaction with biomaterial surfaces |
| WO2009032124A1 (en) | 2007-08-29 | 2009-03-12 | Schering Corporation | Substituted indole derivatives and methods of use thereof |
| EP2195317B1 (en) | 2007-08-29 | 2012-01-18 | Schering Corporation | 2,3-substituted azaindole derivatives for treating viral infections |
| RU2010111550A (ru) | 2007-08-29 | 2011-10-10 | Шеринг Корпорейшн (US) | 2,3-замещенные индольные производные для лечения вирусных инфекций |
| CN101130539B (zh) * | 2007-09-26 | 2012-05-30 | 浙江大学 | 吲哚取代咪唑啉-2-酮类衍生物及其制备方法和用途 |
| US20090098118A1 (en) | 2007-10-15 | 2009-04-16 | Thomas Friess | Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| JP5580814B2 (ja) | 2008-06-13 | 2014-08-27 | メルク・シャープ・アンド・ドーム・コーポレーション | ３環式インドール誘導体およびその使用方法 |
| JP6006292B2 (ja) * | 2011-04-08 | 2016-10-12 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル）Ｉｎｓｅｒｍ（Ｉｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅｌａ Ｓａｎｔｅ Ｅｔ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ｍｅｄｉｃａｌｅ） | インフルエンザウイルス複製を阻害するための方法および医薬組成物 |
| WO2013053045A1 (en) * | 2011-10-12 | 2013-04-18 | Beta Pharma Canada Inc. | Heterocyclic molecules as apoptosis inducers |
| EP2934531A4 (en) * | 2012-12-19 | 2016-06-15 | Glaxosmithkline Llc | COMBINATION |
| CN103044311B (zh) * | 2012-12-26 | 2015-04-22 | 山东大学 | 一种多取代吲哚类化合物及其制备方法和应用 |
| WO2014160071A1 (en) * | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| CN106456699B (zh) | 2014-05-05 | 2021-07-02 | 生物风险投资有限责任公司 | 作为抗老化剂抑制抗凋亡的Bcl-2蛋白的组合物和方法 |
| CA2955972A1 (en) | 2014-07-22 | 2016-01-28 | Bioventures, Llc. | Compositions and methods for selectively depleting senescent cells |
| CN117164657A (zh) | 2014-08-12 | 2023-12-05 | 莫纳什大学 | 定向淋巴的前药 |
| NZ731185A (en) | 2014-10-29 | 2024-03-22 | Bicyclerd Ltd | Bicyclic peptide ligands specific for mt1-mmp |
| WO2016138352A1 (en) | 2015-02-27 | 2016-09-01 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| WO2017021963A1 (en) | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN118063537A (zh) | 2015-09-08 | 2024-05-24 | 莫纳什大学 | 定向淋巴的前药 |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| US20170087125A1 (en) * | 2015-09-30 | 2017-03-30 | Augusta University Research Institute, Inc. | Flavonoid compositions for the treatment of cancer |
| MX389001B (es) | 2015-10-23 | 2025-03-20 | Navitor Pharm Inc | Moduladores de interacción de sestrina-gator2 y sus usos. |
| WO2017106352A1 (en) | 2015-12-14 | 2017-06-22 | Raze Therapeutics, Inc. | Caffeine inhibitors of mthfd2 and uses thereof |
| PT3426243T (pt) | 2016-03-09 | 2021-08-19 | Raze Therapeutics Inc | Inibidores de 3-fosfoglicerato desidrogenase e utilizações dos mesmos |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| US10870640B2 (en) | 2016-04-08 | 2020-12-22 | Institute For Cancer Research | Prodigiosin analogs and methods of use |
| US11337969B2 (en) | 2016-04-08 | 2022-05-24 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| WO2017177216A1 (en) * | 2016-04-08 | 2017-10-12 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Prodigiosin analogs |
| CN109152933B (zh) | 2016-04-21 | 2022-12-02 | 生物风险投资有限责任公司 | 诱导抗细胞凋亡bcl-2家族蛋白的降解的化合物及其用途 |
| EP3808748B1 (en) | 2016-06-21 | 2026-05-20 | X4 Pharmaceuticals, Inc. | Substituted piperidines as cxcr4-inhibitors |
| US10988465B2 (en) | 2016-06-21 | 2021-04-27 | X4 Pharmaceuticals, Inc. | CXCR4 inhibitors and uses thereof |
| TWI763722B (zh) | 2016-10-14 | 2022-05-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| CN110300590A (zh) | 2016-10-21 | 2019-10-01 | 林伯士拉克许米公司 | Tyk2抑制剂及其用途 |
| EP3538091A4 (en) | 2016-11-08 | 2020-06-10 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE MTORC INHIBITORS AND USES THEREOF |
| US20180193270A1 (en) | 2016-11-29 | 2018-07-12 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| ES2985986T3 (es) | 2017-01-06 | 2024-11-08 | Bicyclerd Ltd | Conjugado biciclo para tratar el cáncer |
| AU2018230737B2 (en) | 2017-03-08 | 2022-09-22 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors, uses, and methods for production thereof |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| ES3040534T3 (en) | 2017-04-26 | 2025-11-03 | Navitor Pharm Inc | Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression |
| WO2019002842A1 (en) | 2017-06-26 | 2019-01-03 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF |
| IL317854A (en) | 2017-07-28 | 2025-02-01 | Takeda Pharmaceuticals Co | TYK2 inhibitors and their uses |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| EP4306524A3 (en) | 2017-08-29 | 2024-09-11 | PureTech LYT, Inc. | Lymphatic system-directing lipid prodrugs |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| EP3727362A4 (en) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| ES3041854T3 (en) | 2018-01-22 | 2025-11-17 | Bioventures Llc | Bcl-2 proteins degraders for cancer treatment |
| AU2019212969B2 (en) | 2018-01-29 | 2025-01-23 | Merck Patent Gmbh | GCN2 inhibitors and uses thereof |
| CA3089762A1 (en) | 2018-01-29 | 2019-08-01 | Merck Patent Gmbh | Gcn2 inhibitors and uses thereof |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| KR20260028873A (ko) | 2018-02-27 | 2026-03-04 | 아텍스 바이오파마 인코포레이티드 | Tcr-nck 상호 작용의 억제제로서의 크로멘 유도체 |
| IL301501B2 (en) | 2018-04-24 | 2024-10-01 | Vertex Pharma | Antiproliferation compounds and uses thereof |
| EP3784669B1 (en) | 2018-04-24 | 2023-10-25 | Vertex Pharmaceuticals Incorporated | Pteridinone compounds and uses thereof |
| WO2019221755A1 (en) | 2018-05-18 | 2019-11-21 | Bioventures, Llc | Piperlongumine analogues and uses thereof |
| US10980784B2 (en) | 2018-06-15 | 2021-04-20 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| US11180531B2 (en) | 2018-06-22 | 2021-11-23 | Bicycletx Limited | Bicyclic peptide ligands specific for Nectin-4 |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| EP3846793B1 (en) | 2018-09-07 | 2024-01-24 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| WO2020086816A1 (en) | 2018-10-24 | 2020-04-30 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| WO2020112937A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| EP3897849A1 (en) | 2018-12-21 | 2021-10-27 | BicycleTx Limited | Bicyclic peptide ligands specific for pd-l1 |
| CA3126034A1 (en) | 2019-01-23 | 2020-07-30 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| US20220184222A1 (en) | 2019-04-02 | 2022-06-16 | Bicycletx Limited | Bicycle toxin conjugates and uses thereof |
| KR102980990B1 (ko) | 2019-04-05 | 2026-06-25 | 카이메라 쎄라퓨틱스 인코포레이티드 | Stat 분해제 및 이의 용도 |
| US11458149B1 (en) | 2019-05-31 | 2022-10-04 | Ikena Oncology, Inc. | TEAD inhibitors and uses thereof |
| US12624044B2 (en) | 2019-06-10 | 2026-05-12 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| CA3150492A1 (en) | 2019-09-11 | 2021-03-18 | Donna L. Romero | Usp30 inhibitors and uses thereof |
| US12215105B2 (en) | 2019-09-13 | 2025-02-04 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| AU2020376950B2 (en) | 2019-11-01 | 2026-06-11 | Supernus Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| EP4069223A4 (en) | 2019-12-05 | 2023-12-20 | Janssen Pharmaceutica NV | RAPAMYCIN ANALOGS AND THEIR USES |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| US11679109B2 (en) | 2019-12-23 | 2023-06-20 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| JP7810970B2 (ja) | 2020-02-05 | 2026-02-04 | シーポート・セラピューティクス・インコーポレイテッド | 神経ステロイドの脂質プロドラッグ |
| AR121506A1 (es) | 2020-03-03 | 2022-06-08 | Pic Therapeutics Inc | Inhibidores del eif4e y sus usos |
| WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| AU2021316053A1 (en) | 2020-07-30 | 2023-03-02 | Kymera Therapeutics, Inc. | Methods of treating mutant lymphomas |
| CN116348476A (zh) | 2020-08-03 | 2023-06-27 | 拜斯科技术开发有限公司 | 基于肽的接头 |
| WO2022038158A1 (en) | 2020-08-17 | 2022-02-24 | Bicycletx Limited | Bicycle conjugates specific for nectin-4 and uses thereof |
| EP4232425A4 (en) | 2020-10-23 | 2024-07-24 | Nimbus Clotho, Inc. | Ctps1 inhibitors and uses thereof |
| EP4255895A1 (en) | 2020-12-02 | 2023-10-11 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| KR20230117151A (ko) * | 2020-12-03 | 2023-08-07 | 엔요 파마 | 바이러스 감염을 치료하기 위한 피롤형 화합물 및 이의 용도 |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| EP4255409A1 (en) | 2020-12-07 | 2023-10-11 | Cellestia Biotech AG | Pharmaceutical combinations for treating cancer |
| US12606568B2 (en) | 2020-12-09 | 2026-04-21 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| AR124547A1 (es) | 2020-12-30 | 2023-04-05 | Kymera Therapeutics Inc | Degradadores de irak y sus usos |
| JP2024506858A (ja) | 2021-02-02 | 2024-02-15 | リミナル・バイオサイエンシーズ・リミテッド | Ｇｐｒ８４アンタゴニストおよびその使用 |
| KR20230153387A (ko) | 2021-02-02 | 2023-11-06 | 리미널 바이오사이언시스 리미티드 | Gpr84 길항제 및 이의 용도 |
| WO2022174253A1 (en) | 2021-02-12 | 2022-08-18 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| MX2023009178A (es) | 2021-02-15 | 2023-08-21 | Kymera Therapeutics Inc | Degradadores de la cinasa 4 asociada al receptor de interleucina 1 (irak4) y usos de los mismos. |
| CN117295737A (zh) | 2021-03-05 | 2023-12-26 | 林伯士萨顿公司 | Hpk1拮抗剂和其用途 |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US12325697B2 (en) | 2021-04-09 | 2025-06-10 | Nimbus Clio, Inc. | CBL-B modulators and uses thereof |
| AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CA3217792A1 (en) | 2021-05-07 | 2022-11-10 | Kymera Therapeutics, Inc | Cdk2 degraders and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| IL310924A (en) | 2021-08-25 | 2024-04-01 | Pic Therapeutics Inc | Eif4e inhibitors and uses thereof |
| JP2024540080A (ja) | 2021-10-29 | 2024-10-31 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ４分解剤およびその合成 |
| CN118660886A (zh) | 2021-12-09 | 2024-09-17 | 佛罗里达大学研究基金公司 | 用于治疗癌症的bcl-xl/bcl-2双重降解剂 |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| CN119768393A (zh) | 2022-05-25 | 2025-04-04 | 医肯纳肿瘤学公司 | Mek抑制剂和其用途 |
| EP4565569A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Aryl-triazolyl and related gpr84 antagonists and uses thereof |
| WO2024028365A1 (en) | 2022-08-02 | 2024-02-08 | Liminal Biosciences Limited | Substituted pyridone gpr84 antagonists and uses thereof |
| EP4565568A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| US20250059164A1 (en) | 2023-06-23 | 2025-02-20 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4780462A1 (en) | 2023-09-21 | 2026-07-29 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| WO2025132801A1 (en) | 2023-12-19 | 2025-06-26 | Cimeio Therapeutics Ag | Discernible protein variants of bcl-2 for use in cell therapy |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6134403A (ja) | 1984-07-26 | 1986-02-18 | Nec Corp | 光干渉計 |
| US5274113A (en) | 1991-11-01 | 1993-12-28 | Molecular Probes, Inc. | Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates |
| US5326692B1 (en) | 1992-05-13 | 1996-04-30 | Molecular Probes Inc | Fluorescent microparticles with controllable enhanced stokes shift |
| US5248782A (en) | 1990-12-18 | 1993-09-28 | Molecular Probes, Inc. | Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes |
| US5338854A (en) | 1991-02-13 | 1994-08-16 | Molecular Probes, Inc. | Fluorescent fatty acids derived from dipyrrometheneboron difluoride dyes |
| JPH0586374A (ja) | 1991-09-26 | 1993-04-06 | Teikoku Sekiyu Kk | 炭水化物を可燃性のガスに分解する方法 |
| GB9326284D0 (en) | 1993-12-23 | 1994-02-23 | Erba Carlo Spa | Pyrrolydenemethyl-derivatives and process for their preparation |
| JP3357462B2 (ja) | 1994-06-21 | 2002-12-16 | 協和油化株式会社 | 立体障害性ニトロキシル化合物の製造方法 |
| US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
| EP0756200B1 (en) | 1995-07-26 | 1999-11-10 | Konica Corporation | Silver halide color photographic light-sensitive material |
| US6342477B1 (en) | 1996-02-01 | 2002-01-29 | Chugai Seiyaku Kabushiki Kaisha | Remedies for thrombocytopenia |
| JP3949196B2 (ja) | 1996-10-23 | 2007-07-25 | 赤穂化成株式会社 | 免疫抑制剤 |
| JP3949198B2 (ja) | 1996-10-23 | 2007-07-25 | 赤穂化成株式会社 | Ｖ−ＡＴＰａｓｅ 脱共役 Ｈ＋ ポンプ阻害剤 |
| CN1100777C (zh) * | 1997-02-19 | 2003-02-05 | 伯莱克斯实验室公司 | 作为nos抑制剂的n－杂环衍生物 |
| GB9705035D0 (en) * | 1997-03-11 | 1997-04-30 | Pharmacia & Upjohn Spa | Indolyl-pyrrolydenemethylpyrrole derivatives and process for their preparation |
| US6162520A (en) | 1997-09-17 | 2000-12-19 | Mitsui Chemicals, Inc. | Optical recording medium and dipyrromethene metal chelate compound for use therein |
| GB9726130D0 (en) * | 1997-12-10 | 1998-02-11 | Pharmacia & Upjohn Spa | 2,2'-BI-1H-pyrrole derivatives useful in the treatment of leukemia brought on by HTLV-I |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| DE69935345T3 (de) | 1998-10-23 | 2018-03-01 | Amgen Inc. | Methoden und zusammensetzungen zur prävention und behandlung der anämie |
| AU2164300A (en) | 1998-12-04 | 2000-06-26 | N.V. Organon | Substituted thiazoles for treatment of human diseases involving modulators of p-, l- and e- selectin |
| JP2000275435A (ja) | 1999-03-25 | 2000-10-06 | Sumitomo Chem Co Ltd | 光学異方体フィルムおよび液晶表示装置 |
| JP4085574B2 (ja) | 2000-01-06 | 2008-05-14 | 東レ株式会社 | 発光素子 |
| US6407244B1 (en) * | 2000-01-26 | 2002-06-18 | Gemin X Biotechnologies Inc. | Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases |
| JP2001223082A (ja) | 2000-02-08 | 2001-08-17 | Toray Ind Inc | 発光素子 |
| JP2001223081A (ja) | 2000-02-08 | 2001-08-17 | Toray Ind Inc | 発光素子 |
| JP4058881B2 (ja) | 2000-04-12 | 2008-03-12 | 東レ株式会社 | 発光素子 |
| JP2001307884A (ja) | 2000-04-26 | 2001-11-02 | Toray Ind Inc | 発光素子 |
| JP2001330729A (ja) | 2000-05-23 | 2001-11-30 | Sumitomo Chem Co Ltd | 光学異方体フィルムおよび液晶表示装置 |
| JP2001330730A (ja) | 2000-05-23 | 2001-11-30 | Sumitomo Chem Co Ltd | 光学異方体フィルムおよび液晶表示装置 |
| US7087224B2 (en) | 2000-10-31 | 2006-08-08 | Amgen Inc. | Method of treating anemia by administering IL-1ra |
| US6452014B1 (en) * | 2000-12-22 | 2002-09-17 | Geron Corporation | Telomerase inhibitors and methods of their use |
| DE60223571T2 (de) * | 2001-07-18 | 2008-07-24 | Gemin X Pharmaceuticals Canada. Inc., Montreal | Verbindungen vom pyrroltyp, zusammensetzungen und verfahren zur behandlung von krebs, zur behandlung von virenerkrankungen und zur unterdrückung der immunreaktion |
| WO2004014881A2 (en) | 2002-08-09 | 2004-02-19 | Astra Zeneca Ab | '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5 |
| US20060035945A1 (en) | 2003-05-30 | 2006-02-16 | Giorgio Attardo | Triheterocyclic compounds, compositions, and methods for treating cancer or viral diseases |
| ES2382377T3 (es) | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| WO2005117908A2 (en) | 2004-05-28 | 2005-12-15 | Gemin X Biotechnologies, Inc. | Triheterocyclic compounds compositions, and methods for treating cancer or viral diseases |
| WO2006089397A1 (en) * | 2005-02-22 | 2006-08-31 | Gemin X Biotechnologies Inc. | Methods for treating arthritis using triheterocyclic compounds |
| US20080051400A1 (en) * | 2006-07-06 | 2008-02-28 | Gemin X Biotechnologies Inc. | Methods for treating or preventing anemia or thrombocytopenia using a triheterocyclic compound |
-
2004
- 2004-05-28 ES ES04735171T patent/ES2382377T3/es not_active Expired - Lifetime
- 2004-05-28 SI SI200431872T patent/SI1644363T1/sl unknown
- 2004-05-28 CN CN2004800222923A patent/CN1832939B/zh not_active Expired - Fee Related
- 2004-05-28 RU RU2005141553/04A patent/RU2360913C2/ru not_active IP Right Cessation
- 2004-05-28 CA CA2527583A patent/CA2527583C/en not_active Expired - Fee Related
- 2004-05-28 KR KR1020057022973A patent/KR101168441B1/ko not_active Expired - Fee Related
- 2004-05-28 EP EP04735171A patent/EP1644363B1/en not_active Expired - Lifetime
- 2004-05-28 ZA ZA200509718A patent/ZA200509718B/en unknown
- 2004-05-28 WO PCT/CA2004/000793 patent/WO2004106328A1/en not_active Ceased
- 2004-05-28 AT AT04735171T patent/ATE546456T1/de active
- 2004-05-28 PL PL04735171T patent/PL1644363T3/pl unknown
- 2004-05-28 US US10/857,458 patent/US7425553B2/en not_active Expired - Fee Related
- 2004-05-28 JP JP2006529504A patent/JP4980715B2/ja not_active Expired - Fee Related
- 2004-05-28 PT PT04735171T patent/PT1644363E/pt unknown
- 2004-05-28 HR HRP20120379TT patent/HRP20120379T1/hr unknown
- 2004-05-28 DK DK04735171.3T patent/DK1644363T3/da active
- 2004-05-28 MX MXPA05012799A patent/MXPA05012799A/es active IP Right Grant
- 2004-05-28 BR BRPI0410870-1A patent/BRPI0410870A/pt not_active IP Right Cessation
- 2004-05-28 AU AU2004242928A patent/AU2004242928B2/en not_active Ceased
- 2004-05-28 NZ NZ543897A patent/NZ543897A/xx not_active IP Right Cessation
-
2005
- 2005-11-24 IL IL172189A patent/IL172189A/en not_active IP Right Cessation
- 2005-12-20 NO NO20056057A patent/NO333006B1/no not_active IP Right Cessation
-
2008
- 2008-07-18 US US12/176,123 patent/US20080318902A1/en active Granted
- 2008-07-18 US US12/176,161 patent/US7709477B2/en not_active Expired - Fee Related
-
2011
- 2011-06-29 US US13/171,891 patent/US8420638B2/en not_active Expired - Fee Related
-
2012
- 2012-05-22 CY CY20121100466T patent/CY1113038T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20056057L (no) | Triheterocykliske forbindelser, sammensetninger og fremgangsmater for behandling av cancer og virale sykdommer | |
| BR0309581A (pt) | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c | |
| GEP20063938B (en) | Hepatitis c virus inhibitors | |
| DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
| BRPI0415883A (pt) | compostos e composições de nucleosìdeo para o tratamento de infecções virais | |
| EA200971026A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| MX2009009473A (es) | Compuestos para el tratamiento de hepatitis c. | |
| EA200971041A1 (ru) | Новые пептидные ингибиторы репликации вируса гепатита с | |
| EA201170969A1 (ru) | Новые макроциклические ингибиторы репликации вируса гепатита с | |
| EA200800932A1 (ru) | Модифицированные 4`-нуклеозиды в качестве противовирусных агентов | |
| BRPI0407699A (pt) | Inibidores de rna-polimerase dependente de rna de vìrus de hepatite c e composições e tratamentos que os utilizam | |
| EA200900156A1 (ru) | Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе | |
| ATE525067T1 (de) | Amino-substituierte (e)-2,6-dialkoxystyryl 4- substituierte benzylsulfone zur behandlung von proliferierenden erkrankungen | |
| CY1114356T1 (el) | Αναστολεις του ιου της ηπατιτιδας c | |
| ATE408601T1 (de) | Fredericamycin-derivate | |
| EA200600582A1 (ru) | Способы и композиции для лечения вирусного гепатита с | |
| GEP20084545B (en) | Introducing tlr7 ligands and prodrugs thereof for the treatment of hepatitis c viral infection | |
| EA201100928A1 (ru) | Новые 4-амино-4-оксобутаноил-пептиды как ингибиторы репликации вирусов | |
| NO20052580D0 (no) | Blandinger for behandling av infeksjon av Flavivirida viruser | |
| ES2051641B1 (es) | Procedimientos para la preparacion de compuestos derivados de tiourea. | |
| CY1114865T1 (el) | Νεοι αναστολεις seh και η χρηση toyς | |
| ATE373474T1 (de) | Substituierte 2-aminotetraline zur behandlung von depressionen | |
| DE602008004317D1 (de) | Verbindungen zur behandlung von hepatitis c | |
| DE602004008959D1 (de) | Benzoäbüä1,4üdioxepinderivate | |
| MXPA02007271A (es) | Compuestos de tipo pirrol, composiciones que los contienen, y metodos para el tratamiento de cancer o enfermedades virales. |